The lineup for this year's Indiana Life Sciences Summit in Indianapolis includes executives from some of the top employers in the state. The October event will also feature a keynote speech from the director of the National Institutes of Health's National Center for Advancing Translation Sciences. Inside INdiana Business Host Gerry Dick will moderate two industry panels. August 18, 2014

News Release

INDIANAPOLIS, Ind. – BioCrossroads and AlpInvest Partners today announced their speaker line up for their eleventh annual Indiana Life Sciences Summit on Wednesday, October 15, 2014. Christopher Austin, M.D., director of the National Institutes of Health's National Center for Advancing Translation Sciences (NCATS), will deliver the keynote address on accelerating research. Leaders from Cook Medical, Roche Diagnostics, Transcelerate BioPharma, Flexion Therapeutics, the State Science and Technology Institute, among others, will be providing their perspectives on topics relevant to Indiana's life sciences industry as well as global trends.

Austin, who served as director of the NCATS Division of Pre-Clinical Innovation since the creation of the Center in December 2011, is leading NCATS in its mission to catalyze the generation of innovative methods and technologies that will enhance the development, testing and implementation of diagnostics and therapeutics across a wide range of human diseases and conditions. Austin is applying his experience across the spectrum of translational research to identify commonalities among diseases and implement a system-wide approach to accelerating the translational science process, thus speeding the delivery of interventions that improve human health.

Austin came to NIH in 2002 from Merck, where his work focused on genome-based discovery of novel targets and drugs. He began his career at NIH as the senior advisor to the director for translational research at the National Human Genome Research Institute, where he initiated the Knockout Mouse Project and the Molecular Libraries Roadmap Initiative. Other NIH roles have included serving as director of the Therapeutics for Rare and Neglected Diseases program as well as the NIH Chemical Genomics Center and as scientific director of the NIH Center for Translational Therapeutics.

Austin earned an A.B. summa cum laude in biology from Princeton University and an M.D. from Harvard Medical School. He completed clinical training in internal medicine and neurology at Massachusetts General Hospital, and a research fellowship in genetics at Harvard.

Panel topics and additional speakers include:

Exploring New Avenues to Accelerate Research

-Debra Lappin, President, Council for American Medical Innovation and Principal, Faegre Baker Daniels Consulting

-Michael D. Clayman, M.D., CEO, Flexion Therapeutics

-Annalisa Jenkins, M.D., Chair of the Board, TransCelerate BioPharma

-Jack Phillips, President and CEO, Roche Diagnostics

-Pete Yonkman, President, Cook Medical

Indiana Biosciences Research Institute’s Approach to Quicker Commercialization

-Gerry Dick, Host, Inside Indiana Business and Founder, Grow Indiana

-David Broecker, Interim Chief Operating Officer, Indiana Biosciences Research Institute

-Andrew Dahlem, D.V.M. (h.c.), Ph.D., Vice President, LRL Operations/LRL Europe,

Eli Lilly and Company

-Jay Hess, M.D., Ph.D., M.H.S.A., Dean, Indiana University School of Medicine; Vice President for University Clinical Affairs, Indiana University

-Luke Kenley, Senator, Indiana State Senate

The Need for Capital and its Impact on Innovation and Research

-Nadim Barakat, Managing Director, Carlyle Group

-Mark Skinner, Vice President of the State Science & Technology Institute

-Derek Small, Co-Founder and Executive Chairman, Assembly Pharmaceuticals

The Summit will be at the JW Marriott, downtown Indianapolis. The networking reception hosted by Eli Lilly and Company and Cook Medical will be from 6:00 p.m. to 8:00 p.m. on Tues., Oct. 14. Winners of the New Venture Competition will also be announced that evening. Sponsors of the conference include Faegre Baker Daniels, Roche Diagnostics, Miles Printing, Indiana University, Indiana Economic Development Corporation, Bloomberg Government, and the Indiana Biosciences Research Institute.

More information and registration here:

About BioCrossroads

BioCrossroads ( advances Indiana’s signature strengths in the life sciences by connecting with corporate, academic and philanthropic partners; facilitating investments in promising start ups and building new enterprises; and educating through conferences, reports and market development knowledge. The initiative supports the region's existing research and corporate strengths while encouraging new business development and has formed several new nonprofit organizations, including Indiana Health Information Exchange, Fairbanks Institute for Healthy Communities, BioCrossroadsLINX, OrthoWorx, and Datalys Center.

Source: BioCrossroads

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}